<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01468389</url>
  </required_header>
  <id_info>
    <org_study_id>AGC001-307PLAH-XJM</org_study_id>
    <nct_id>NCT01468389</nct_id>
  </id_info>
  <brief_title>Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric Junction</brief_title>
  <official_title>A Randomized Multicenter Phase III Study:Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone vs.Taxanes or Platinum Combined With Capecitabine in Advanced Adenocarcinoma of the Stomach or Esophagogastric Junction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Hospital of the Chinese Academy of Military Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Hospital of the Chinese Academy of Military Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether Taxanes or Platinum Plus Capecitabine
      With Capecitabine Maintenance Treatment as 1st line treatment in he advanced gastric cancer
      is effective and safe.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Taxanes or Platinum in combination with Capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients will received chemotherapy combining capecitabine with platinum or taxanes until progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy followed by capecitabine alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients who has received 4 cycle chemotherapy combining capecitabine with platinum or taxanes and the result was SD or CR or PR,will be given capecitabine alone until progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>900-1000mg/m2 bid, days 1-14, every 3 weeks</description>
    <arm_group_label>Taxanes or Platinum in combination with Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>Dosing schedule: 900-1000mg/m2 bid, days 1-14, every 3 weeks Maintenance dosing schedule: 1000-1250mg/m2 bid, days 1-14, every 3 weeks</description>
    <arm_group_label>chemotherapy followed by capecitabine alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Having signed informed consent

          2. Age≥ 18 years old

          3. Histologically confirmed gastric adenocarcinoma

          4. Unresectable recurrent or metastatic disease

          5. Previous neo-adjuvant or adjuvant treatment for gastric cancer, if applicable, more
             than 6 months

          6. Previous chemotherapy with oxaliplatin or cisplatin or paclitaxel or docetaxel, if
             applicable, more than 12 months.

          7. Measurable disease according to the RECIST criteria

          8. ECOG performance status ≤2

          9. Life expectancy of ≥3 month

         10. No prior radiotherapy except radiotherapy at non-target lesion of the study more than
             4 weeks

         11. ALT and AST≤2.5 times ULN (≤5 times ULN in patients with liver metastases) Serum
             albumin level ≥3.0g/dL Serum creatinine ≤1.5ULN Bilirubin level ≤ 1.5 ULN
             WBC&gt;3,000/mm3, absolute neutrophil count ≥1500/mm3, platelet&gt;90,000/mm3, Hb&gt;8g/dl

        Exclusion Criteria:

          1. Brain metastasis (known or suspected)

          2. Previous systemic therapy for metastatic gastric cancer

          3. Inability to take oral medication

          4. Previous therapy targeting at angiogenesis or vasculogenesis pathway or other targeted
             therapy

          5. Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry

          6. Allergic constitution or allergic history to any investigating agents.

          7. Severe heart disease or such history as recorded congestive heart failure,
             uncontrolled cardiac arrhythmia, angina pectoris needing medication, cardiac valve
             disease, severe abnormal ECG findings, cardiac infarction , or retractable
             hypertension.

          8. Pregnancy or lactation period

          9. Any investigational agent within the past 28 days

         10. Other previous malignancy within 5 year

         11. Pre-existing neuropathy&gt;grade 1

         12. Legal incapacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xu jianming, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Affiliated Hospital of the Chinese Academy of Military Medical Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xu jianming, M.D.</last_name>
    <phone>861051128358</phone>
    <email>jmxu2003@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>307 Hospital of PLA</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu jianming, M.D.</last_name>
      <phone>86-10-66947176</phone>
      <email>jmxu2003@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhao chuanhua</last_name>
      <phone>86-10-66947179</phone>
      <email>chuanhuazhao@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2011</study_first_submitted>
  <study_first_submitted_qc>November 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <last_update_submitted>November 8, 2011</last_update_submitted>
  <last_update_submitted_qc>November 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Hospital of the Chinese Academy of Military Medical Sciences</investigator_affiliation>
    <investigator_full_name>Xu jianming</investigator_full_name>
    <investigator_title>The Affiliated Hospital of the Chinese Academy of Military Medical Sciences</investigator_title>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>capecitabine</keyword>
  <keyword>maintenance treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Taxane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

